Premium Nahrungsergänzungsmittel | artgerecht

Mazdutide – Dual GLP-1/GCG Agonist for Obesity

Mazdutide is a dual GLP-1/GCG receptor agonist under clinical development for the treatment of obesity and type 2 diabetes. It mimics the action of naturally occurring metabolic hormones.

Regular tips about health Regular tips about health

Things worth knowing about "Mazdutide"

Mazdutide is a dual GLP-1/GCG receptor agonist under clinical development for the treatment of obesity and type 2 diabetes. It mimics the action of naturally occurring metabolic hormones.

What is Mazdutide?

Mazdutide is an investigational drug belonging to the class of dual receptor agonists that simultaneously activates both the GLP-1 receptor (glucagon-like peptide-1) and the glucagon receptor (GCG receptor). It is currently being evaluated in clinical trials primarily for the treatment of obesity and type 2 diabetes mellitus. Mazdutide was developed by the Chinese biopharmaceutical company Innovent Biologics and is in advanced stages of clinical testing.

Mechanism of Action

Mazdutide works on two complementary hormonal systems simultaneously:

GLP-1 receptor activation: Stimulating the GLP-1 receptor promotes glucose-dependent insulin secretion from the pancreas, suppresses glucagon release, and slows gastric emptying. This results in improved blood glucose control and a reduced appetite.
Glucagon receptor activation: Co-activation of the glucagon receptor increases energy expenditure, promotes hepatic fat oxidation (lipolysis), and supports the reduction of visceral adipose tissue. Glucagon also raises basal metabolic rate, amplifying the weight-reducing effect.

The combination of both mechanisms is intended to achieve a stronger weight-lowering effect than GLP-1 activation alone, without negatively impacting blood glucose levels.

Indications

Obesity and Overweight

In clinical trials, Mazdutide demonstrated significant body weight reduction in individuals with obesity (BMI ≥ 30 kg/m²) or overweight with comorbidities. Weight loss is achieved through a combination of reduced appetite, slowed gastric emptying, and increased energy expenditure.

Type 2 Diabetes Mellitus

In patients with type 2 diabetes, Mazdutide improves glycemic control through glucose-dependent insulin stimulation. Clinical data show a significant reduction in HbA1c levels as well as fasting blood glucose.

Non-Alcoholic Fatty Liver Disease (NAFLD/NASH)

Due to its effects on hepatic lipid oxidation and visceral fat reduction, Mazdutide is also being investigated as a potential treatment for non-alcoholic fatty liver disease (NAFLD) and its advanced form, NASH (non-alcoholic steatohepatitis).

Dosage and Administration

Mazdutide is administered as a subcutaneous injection (under the skin), typically once weekly. Exact dosing regimens vary by study and indication. Clinical trials have investigated doses ranging from 3 mg to 9 mg per week, with gradual dose escalation to improve tolerability.

Side Effects

The side effect profile of Mazdutide is comparable to other GLP-1 receptor agonists. The most commonly reported side effects include:

Nausea and vomiting (especially at the start of treatment)
Diarrhea or constipation
Decreased appetite
Abdominal pain
Injection site reactions

Serious adverse events such as pancreatitis (inflammation of the pancreas) are known within this drug class and have been observed in studies. Patients with a history of pancreatitis should exercise particular caution.

Clinical Evidence

Mazdutide has undergone multiple Phase II and Phase III clinical trials. Key studies include:

GLORY clinical program: A series of Phase III trials conducted in China examining the efficacy and safety of Mazdutide for obesity and type 2 diabetes.
Phase II study results showed an average weight reduction of up to 11% from baseline after 24 weeks at the highest dose.
HbA1c reductions of up to 1.8% were observed in diabetes studies.

Mazdutide has not yet received approval from regulatory authorities such as the EMA (European Medicines Agency) or the FDA (U.S. Food and Drug Administration) and is therefore not yet an approved medication.

Comparison with Other Agents

Mazdutide belongs to the group of incretin mimetics and is related to already approved GLP-1 agonists such as semaglutide or liraglutide. The key difference lies in the additional activation of the glucagon receptor, resulting in higher energy expenditure and enhanced fat burning. Other dual or triple receptor agonists such as tirzepatide (GLP-1/GIP) or retatrutide (GLP-1/GIP/GCG) pursue similar but distinct combination strategies.

References

Ji L. et al. - Efficacy and Safety of Mazdutide in Chinese Adults with Overweight or Obesity: A Phase 2, Randomised, Double-blind, Placebo-controlled Trial. The Lancet Regional Health - Western Pacific, 2023.
Innovent Biologics - Clinical Pipeline and Study Results for Mazdutide (IBI362), innoventbio.com, 2023.
Muller T.D. et al. - Glucagon-like Peptide 1 (GLP-1). Molecular Metabolism, 2019. DOI: 10.1016/j.molmet.2019.09.010.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category